Return to Listing

1 result(s) for LGX818

PI Name Protocol # Title
Matthew Taylor IRB00010630 CLGX818X2109: The LOGIC 2 trial, A phase II, multi-center, open-label study of sequential LGX818/MEK162 combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080